TY - JOUR TI - Treatment of severe hypocalcaemia due to osteoblastic metastases in a patient with post-thyroidectomy hypoparathyroidism with 153 Sm-EDTMP AU - Kassi, E. AU - Kapsali, I. AU - Kokkinos, M. AU - Gogas, H. JO - BMJ Case Reports PY - 2017 VL - 2017 TODO - null SP - null PB - BMJ Publishing Group SN - 1757-790x TODO - 10.1136/bcr-2017-219354 TODO - alfacalcidol; calcium; calcium carbonate; carboplatin; citrate calcium; colecalciferol; levothyroxine; lexidronam samarium sm 153; magnesium; paclitaxel; zoledronic acid; analgesic agent; calcium; organometallic compound; organophosphorus compound; radioisotope; samarium Sm-153 lexidronam, aged; anamnesis; Article; bone metastasis; breast cancer; calcium blood level; cancer combination chemotherapy; cancer hormone therapy; cancer radiotherapy; case report; computer assisted tomography; differential diagnosis; dose response; drug dose reduction; female; hormone substitution; hospital discharge; human; hypocalcemia; hypoparathyroidism; hypothyroidism; liver metastasis; postoperative complication; priority journal; simple mastectomy; spleen metastasis; thyroidectomy; toxic goiter; treatment duration; blood; bone tumor; breast tumor; complication; hypocalcemia; hypoparathyroidism; intravenous drug administration; osteoblast; pathology; postoperative complication; secondary; thyroidectomy; treatment outcome, Administration, Intravenous; Aged; Analgesics, Non-Narcotic; Bone Neoplasms; Breast Neoplasms; Calcium; Diagnosis, Differential; Female; Humans; Hypocalcemia; Hypoparathyroidism; Organometallic Compounds; Organophosphorus Compounds; Osteoblasts; Postoperative Complications; Radioisotopes; Thyroidectomy; Treatment Outcome TODO - Symptomatic hypocalcaemia is an uncommon finding in patients with malignant tumours. We describe a patient with advanced metastatic breast cancer who developed severe hypocalcaemia caused by the combination of osteoblastic metastases and a permanent postoperative hypoparathyroidism. The patient failed to be treated with the conventional replacement therapy and was submitted effectively to radionucleotide therapy with 153 Sm. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ER -